拉夏貝爾(06116.HK):至上月底累涉訴訟案件22宗
拉夏貝爾(06116.HK)公布,4月累計新增訴訟案件7宗,新增訴訟涉案金額約3,358萬元人民幣(下同)。截至今年4月30日,公司累計涉及未審結/未調解訴訟案件22宗,未決訴訟案件涉案金額約為12.46億元,當中集團為被告涉案金額約12.28億元。
截至今年4月30日,集團共計103個銀行賬戶被凍結,被凍結銀行賬戶的凍結金額約為2,300萬元。另外,因集團涉及訴訟案件等影響,共計導致公司下屬11間子公司股權被凍結,涉及案件執行金額合計約2.02億元。
公司並因涉及金融借款糾紛、施工合同糾紛等共計13項訴訟案件,導致公司2處不動產被查封。截止今年3月31日的賬面價值合計約為3.23億元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.